Cargando…

Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies

PURPOSE OF REVIEW: The evolving information of the initiation, tumor cell heterogeneity, and plasticity of childhood neuroblastoma has opened up new perspectives for developing therapies based on detailed knowledge of the disease. RECENT FINDINGS: The cellular origin of neuroblastoma has begun to un...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundberg, Kristina Ihrmark, Treis, Diana, Johnsen, John Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249718/
https://www.ncbi.nlm.nih.gov/pubmed/35362827
http://dx.doi.org/10.1007/s11912-022-01270-8
_version_ 1784739648259489792
author Lundberg, Kristina Ihrmark
Treis, Diana
Johnsen, John Inge
author_facet Lundberg, Kristina Ihrmark
Treis, Diana
Johnsen, John Inge
author_sort Lundberg, Kristina Ihrmark
collection PubMed
description PURPOSE OF REVIEW: The evolving information of the initiation, tumor cell heterogeneity, and plasticity of childhood neuroblastoma has opened up new perspectives for developing therapies based on detailed knowledge of the disease. RECENT FINDINGS: The cellular origin of neuroblastoma has begun to unravel and there have been several reports on tumor cell heterogeneity based on transcriptional core regulatory circuitries that have given us important information on the biology of neuroblastoma as a developmental disease. This together with new insight of the tumor microenvironment which acts as a support for neuroblastoma growth has given us the prospect for designing better treatment approaches for patients with high-risk neuroblastoma. Here, we discuss these new discoveries and highlight some emerging therapeutic options. SUMMARY: Neuroblastoma is a disease with multiple facets. Detailed biological and molecular knowledge on neuroblastoma initiation, heterogeneity, and the communications between cells in the tumor microenvironment holds promise for better therapies.
format Online
Article
Text
id pubmed-9249718
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-92497182022-07-03 Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies Lundberg, Kristina Ihrmark Treis, Diana Johnsen, John Inge Curr Oncol Rep Pediatric Oncology (KL Davis, Section Editor) PURPOSE OF REVIEW: The evolving information of the initiation, tumor cell heterogeneity, and plasticity of childhood neuroblastoma has opened up new perspectives for developing therapies based on detailed knowledge of the disease. RECENT FINDINGS: The cellular origin of neuroblastoma has begun to unravel and there have been several reports on tumor cell heterogeneity based on transcriptional core regulatory circuitries that have given us important information on the biology of neuroblastoma as a developmental disease. This together with new insight of the tumor microenvironment which acts as a support for neuroblastoma growth has given us the prospect for designing better treatment approaches for patients with high-risk neuroblastoma. Here, we discuss these new discoveries and highlight some emerging therapeutic options. SUMMARY: Neuroblastoma is a disease with multiple facets. Detailed biological and molecular knowledge on neuroblastoma initiation, heterogeneity, and the communications between cells in the tumor microenvironment holds promise for better therapies. Springer US 2022-04-01 2022 /pmc/articles/PMC9249718/ /pubmed/35362827 http://dx.doi.org/10.1007/s11912-022-01270-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pediatric Oncology (KL Davis, Section Editor)
Lundberg, Kristina Ihrmark
Treis, Diana
Johnsen, John Inge
Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
title Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
title_full Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
title_fullStr Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
title_full_unstemmed Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
title_short Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
title_sort neuroblastoma heterogeneity, plasticity, and emerging therapies
topic Pediatric Oncology (KL Davis, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249718/
https://www.ncbi.nlm.nih.gov/pubmed/35362827
http://dx.doi.org/10.1007/s11912-022-01270-8
work_keys_str_mv AT lundbergkristinaihrmark neuroblastomaheterogeneityplasticityandemergingtherapies
AT treisdiana neuroblastomaheterogeneityplasticityandemergingtherapies
AT johnsenjohninge neuroblastomaheterogeneityplasticityandemergingtherapies